Commitment to transparency and access

Physician Payments Sunshine Act

GSK was among the first companies to voluntarily disclose information publicly about our work with health care professionals, including fees for speaking and consulting, which we have posted publicly since 2009. Most recently, GSK began disclosing payments to institutions and lead investigators for assisting with clinical research studies that started after Jan. 1, 2010.

We are committed to doing our part to further improve transparency and to continue to build trust among our patients and our customers.

The Physician Payments Sunshine Act
A new federal law (effective January 1, 2012) requires drug and medical device manufacturers, including GlaxoSmithKline, to track and report to the government certain “transfers of value” made to U.S. health care professionals and U.S. teaching hospitals. These legally permitted transfers of value include meals, reimbursed travel expenses, consulting fees, and honoraria in addition to a broad range of other items listed in the law.

The Physician Payments Sunshine Act aligns with GSK’s corporate value of transparency.  The company has worked to comply with its provisions as well as additional disclosure requirements established by various states. 

Beginning January 1, 2012, GSK and other pharmaceutical companies must begin recording all transfers of value to health care professionals and teaching hospitals.

On March 31, 2013, companies are expected to file their reports for the 2012 calendar year to the Department of Health and Human Services. Following this first report, companies will report this data on an annual basis.

By September 30, 2013, the government will publicly post 2012 data for all companies on a federal website.